News | October 04, 2024
SK pharmteco invests US$ 260 million to expand global small molecule, peptide production
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Subscribe To Our Newsletter & Stay Updated
